Humana faces significant earnings headwinds due to CMS reforms, star rating downgrades, and potential Medicaid clawbacks.

Humana’s stock performance and market strategies continue to be closely monitored by investors and analysts, with particular attention to how the company navigates industry challenges.

UnitedHealth's dip offers long-term value, backed by strong fundamentals, rising dividends, and growth potential. Learn why ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Raymond (NSE:RYMD) James has upgraded Humana’s stock rating from Market Perform to Outperform, setting a new price target of $315, citing the company’s strong performance and favorable drug mix.

While robust first-quarter earnings and operational performance were reported ... Unlock comprehensive insights into our analysis of Humana stock in this financial health report.

Shares of Humana Inc. rallied 3.94% to $247.34 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.09% to 5,963.60 and the Dow ...

High-rolling investors have positioned themselves bullish on Humana ... performance Trading volume stands at 342,251, with HUM's price down by -1.52%, positioned at $249.5. RSI indicators show the ...

The performance and reduced forecast led to a ... The warning about healthcare costs dragged other insurer stocks, with Humana (HUM), CVS Health (CVS), and Elevance Health (ELV) also among the ...

Humana’s stock performance and market strategies continue to be closely monitored by investors and analysts, with particular attention to how the company navigates industry challenges. In other recent ...